SIGNABLOK, INC.
Ligand-independent TREM-1 inhibitory peptides (GF9, GA31, GE31) formulated into macrophage-specific lipopeptide complexes for rheumatoid arthritis treatment
- Sector
- Biotech
- Headquarters
- Worcester, MA
- Total capital
- $7.3M
- Federal grants
- $7M
- 16 awards · 2015–2026
- Rank in peer group#87 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $370K
- 2 awards · Defense
- Rank in Biotech#246 of 4373
- Granted patents
- 6
- 7 pending · first 2020
- Rank in peer group#58 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · First-in-class TREM-1 inhibitors for neovascular retinal diseases$830K
- Federal grantHealth and Human S · Phase I · TREM-1 therapy for the treatment of empyema$458K
- Federal grantHealth and Human S · Phase II · First-in-class TREM-1 inhibitors for neovascular retinal diseases$830K
- Federal grantHealth and Human S · Phase II · First-in-class TREM-1 inhibitors for neovascular retinal diseases$278K
- Federal grantHealth and Human S · Phase I · New mechanism-based TREM-1 therapy for acute respiratory distress syndrome$273K
- Federal grantHealth and Human S · Phase I · TREM-1 inhibitor for the treatment of scleroderma$250K
- Federal grantHealth and Human S · Phase I · TREM-1 therapy for rheumatoid arthritis$259K
Show 11 earlier federal awards
- Federal grantHealth and Human S · Phase II · First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$1.2M
- Federal contractDefense · Dha Medical R&d,sbir Phase I Purchase Order For Proposal No. H201-002-0001 Titled,"first-in-class TREM-1 Radioprotector To Prevent The Effects Of Acute Radiation Syndrome"$220K
- Federal grantHealth and Human S · Phase II · First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$800K
- Federal grantHealth and Human S · Phase I · First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$2K
- Federal grantHealth and Human S · Phase I · Novel TREM-1 targeting therapies for sepsis$225K
- Federal grantHealth and Human S · Phase I · Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases$226K
- Federal grantHealth and Human S · Phase I · First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$225K
- Federal grantHealth and Human S · Phase I · Treatment of alcoholic liver disease with novel targeted inhibitors$223K
- Federal grantHealth and Human S · Phase I · Development of novel targeted agents in pancreatic cancer$220K
- Federal grantHealth and Human S · Phase II · Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$673K
- Federal contractDefense · Contract Award$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#87 · top 17%
- Granted patents#58 · top 11%
- Linked publications#43 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 6 granted of 13- PendingMethods And Compositions For Targeted Delivery Of Protein FragmentsUSPTOApplication 19308843
- GrantedMethods And Compositions For Targeted Delivery Of Protein FragmentsUSPTOUS 12,419,839
- PendingInhibition Of Trem Receptor Signaling With Peptide VariantsUSPTOApplication 18960346
Show all 13 patent records
- Methods And Compositions For Targeted Delivery Of Protein FragmentsFeb 19, 2026 · Application 19308843Pending
- Methods And Compositions For Targeted Delivery Of Protein FragmentsSep 23, 2025 · US 12,419,839Granted
- Inhibition Of Trem Receptor Signaling With Peptide VariantsMay 15, 2025 · Application 18960346Pending
- Inhibition Of Trem Receptor Signaling With Peptide VariantsDec 17, 2024 · US 12,168,034Granted
- METHODS FOR TARGETED IMAGING WITH SPHERICAL rHDLsSep 19, 2024 · Application 18736873Pending
- Spherical rHDLs For Targeted ImagingJul 16, 2024 · US 12,036,294Granted
- Inhibition Of Trem Receptor Signaling With Peptide VariantsMay 2, 2023 · US 11,638,739Granted
- Peptides And Compositions For Targeted Treatment And ImagingOct 21, 2021 · Application 17268046Pending
- Methods And Compositions For Targeted ImagingJan 19, 2021 · US 10,894,098Granted
- Inhibition Of TCR Signaling With Peptide VariantsApr 23, 2020 · Application 16719103Pending
- Inhibition Of Tcr Signaling With Peptide VariantsJan 21, 2020 · US 10,538,558Granted
- Peptides And Compositions For Targeted Treatment And ImagingApplication PCTUS2019046392Pending
- Trifunctional Peptides And Compositions For Targeted Treatment And ImagingApplication 62751303Pending
Recent research by its founders
- Abstract 2891: Specificity and timing of TREM-1 blockade initiation impact its therapeutic efficacy in cancer20260 cites
- Abstract LB128: Timely resolution of TREM-1-mediated inflammation after chemotherapy improves complete response rate and survival in experimental pancreatic cancer20252 cites
- Ligand-Independent TREM-1 Blockade Ameliorates Pulmonary Inflammation and Fibrosis20252 cites
Related companies, and why
- TRITERPENOID THERAPEUTICS INCSimilar federal contract value in Biotech · $400K in contracts
- ENRICH BIOSYSTEMS INCSimilar federal contract value in Biotech · $400K in contracts
- CYTOBIOSCIENCE INCSimilar federal contract value in Biotech · $387K in contracts
- NUVOX PHARMA, L.L.C.Similar federal contract value in Biotech · $356K in contracts
- CLOVERLEAF BIO, INC.Similar federal contract value in Biotech · $355K in contracts
- MATRISOME BIO, INC.Similar federal contract value in Biotech · $354K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .